OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.
- FDA moves OncoSil’s HDE application to final review
- TRIPP-FFX trial meets co-primary endpoints with encouraging survival
- OncoSil targets rare distal cholangiocarcinoma and unresectable pancreatic cancer
- Potential US market entry within months pending final submissions
- Label expansion planned to include FOLFIRINOX chemotherapy
OncoSil Nears FDA Approval for Rare Bile Duct Cancer Device
OncoSil Medical (ASX:OSL) has reached the final administrative stage of the FDA’s review for its Humanitarian Device Exemption (HDE) application, a critical step toward US approval of its OncoSil™ device for treating distal cholangiocarcinoma (dCCA), a rare and aggressive bile duct cancer. The FDA confirmed on 3 June that all outstanding questions have been satisfactorily addressed and has requested only final device labelling and any updates to post-market study plans before completing its review within 45 days of submission.
HDE status is designed for devices addressing conditions affecting fewer than 8,000 patients annually in the US, offering a streamlined approval pathway without the costly and lengthy Phase III trials typical of pre-market approvals. For OncoSil, this could mean earlier commercial access in the US market for a disease with limited treatment options and poor prognosis, where median survival without treatment is around six months.
TRIPP-FFX Trial Validates OncoSil with Standard Chemotherapy
Alongside the regulatory update, OncoSil reported positive preliminary results from its TRIPP-FFX Phase II trial, which assessed the safety and efficacy of OncoSil combined with FOLFIRINOX chemotherapy in patients with unresectable locally advanced pancreatic cancer (LAPC). The trial met both co-primary endpoints, demonstrating a local disease control rate (LDCR) of 82.2% at 16 weeks and a median overall survival of 18.3 months, outcomes that compare favourably to historical benchmarks.
Investigators noted that toxicities from adding OncoSil to FOLFIRINOX were limited and manageable, supporting the device’s safety profile. The study was not powered for direct statistical comparison between arms but used a randomized design with a historical control benchmark. These results align with prior data from the PANCO study and real-world registries, reinforcing OncoSil’s potential to improve outcomes in a notoriously difficult-to-treat cancer.
Strategic Pathway to Market and Label Expansion
OncoSil plans to submit the requested final labelling and post-market study information to the FDA within 30 days, aiming for potential HDE approval by late 2026. This milestone would mark the company’s first US regulatory approval and open the world’s largest medical device market to OncoSil’s targeted radiation therapy.
In parallel, OncoSil intends to file a Change Notification to its EU Notified Body to expand the OncoSil product label to include FOLFIRINOX chemotherapy, facilitating accelerated market penetration in Europe and strengthening physician adoption. The company also anticipates launching the device in Australia and the US in 2026–2027, contingent on regulatory approvals.
Clinical Impact on Rare and Challenging Cancers
dCCA is a rare cancer with limited treatment options and poor survival rates, often diagnosed too late for surgical removal. OncoSil’s approach delivers radioactive phosphorus-32 microparticles directly into tumours, enabling higher radiation doses with fewer side effects compared to external beam radiotherapy. This targeted method aims to control tumour growth locally, maintain bile duct patency, and improve quality of life for patients who typically face repeated hospital admissions due to stent occlusion and infection.
Similarly, in unresectable pancreatic cancer, OncoSil’s combination with FOLFIRINOX offers hope for better disease control and extended survival, as evidenced by the TRIPP-FFX trial’s encouraging data. Principal investigators from the University of Verona highlighted the clinical significance of these findings and the potential to downstage patients towards surgical resection.
Upcoming Milestones to Watch
Key upcoming events include the submission of final FDA HDE documentation within 30 days, anticipated FDA decision within 45 days thereafter, and the presentation of TRIPP-FFX initial results at a major oncology congress in the second half of 2026. The company is also progressing manufacturing validation at its Sydney facility to support commercial launch.
OncoSil’s regulatory and clinical advances position it at a pivotal juncture, with potential US market entry on the horizon and a growing body of evidence supporting its targeted radiotherapy device in difficult-to-treat cancers.
Bottom Line?
OncoSil stands on the cusp of US approval and broader clinical adoption, but final FDA sign-off and successful commercial execution will be decisive for its growth trajectory.
Questions in the middle?
- Will FDA approval of the HDE application catalyse US commercial uptake for OncoSil?
- How will the planned label expansion to include FOLFIRINOX affect OncoSil’s market penetration in Europe?
- What patient subgroups might benefit most from OncoSil’s targeted therapy in pancreatic cancer?